CLINICAL CHARACTERISTICS OF COVID-19 AND THE EFFICACY OF VACCINATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

  • Olivera Markovic Associate professor
  • Anica Divac dr
  • Ilija Bukurecki MD
  • Marija Brankovic Assistant of Professor
  • Igor Jovanovic MD, PhD
  • Predrag Đuran
  • Marija Zdravkovic Assistant professor
DOI: https://doi.org/10.5937/3-35474
Keywords: COVID-19, hematologic malignancies, vaccine

Abstract


Patients with hematologic malignancies are at increased risk of severe forms of COVID-19 and have higher mortality, compared to patients with COVID-19 in the general population. The reasons for this include immunosuppression caused by the underlying hematologic disease and/or anticancer therapy received by these patients, advanced age, but also low levels of seroconversion after vaccination. These patients are also at a higher risk of getting infected because of frequent visits to health care facilities and high exposure to other patients. Results from published studies highlight the importance of prevention strategies in these patients, based on infection control measures and physical distancing, but also on well-timed vaccination. Risk factors which have proven to be crucial for severe forms of COVID-19 are age, the presence of comorbidities, malignancy type, progressive disease, and the type of oncologic therapy that these patients receive. Therefore, patients with hematologic malignancies represent a priority group for vaccination, which is recommended by all international professional associations. Considering that these patients are at risk of not developing an adequate immune response to the vaccine, the issues of determining the optimal time period for receiving the vaccine, the optimal dose, and the capacity of developing an immune response to the vaccine in specific groups of patients with hematologic malignancies, are questions that remain unresolved. Studies have shown that, despite the weak immune response to the vaccine, the mortality of vaccinated patients with hematologic malignancies is significantly lower than the mortality of unvaccinated patients. This article provides a review of relevant studies which analyze the characteristics, morbidity and mortality of patients with hematologic malignancies and COVID-19 and the role of vaccination in these patients.

References


  1. World Health Organization. (n.d.). Who director-general's opening remarks at the media briefing on COVID-19 - 11 march 2020. World Health Organization. Retrieved December 5, 2021. available: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020.

  2. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E et al. Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2021. available: https://ourworldindata.org/coronavirus-data

  3. Sanchez‐Pina, J. M, Rodríguez Rodriguez, M, Castro Quismondo, N, Gil Manso, R, Colmenares, R, Gil Alos, D. et al. Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies. European Journal of Haematology 2020; 105(5):597–607.

  4. Vijenthira, A, Gong, IY, Fox TA, Booth S, Cook G, FattizzoB, Martín-Moro F. et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood 2020; 136(25):2881–92.

  5. García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste, et al. Asociación Madrileña de Hematología y Hemoterapia (AMHH). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. Journal of Hematology & Oncology 2020;13(1):133-8.

  6. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020; 7e:737–45

  7. Pagano, L, Salmanton-García, J, Marchesi, F, Busca, A, Corradini, P, Hoenigl, M. et al.COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology & Oncology 2021; 14(1):168-74.

  8. Mortality analyses. Johns Hopkins Coronavirus Resource Center. (n.d.). Retrieved December 12, 2021, available: https://coronavirus.jhu.edu/data/mortality.

  9. Giannakoulis VG, Papoutsi E, & Siempos II. Effect of Cancer on Clinical Outcomes of Patients with COVID-19: A Meta-Analysis of Patient Data. JCO Global Oncology 2020; 6: 799–808.

  10. Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, Turgut B, & Altuntas F. The outcome of COVID-19 in patients with hematological malignancy. Journal of medical virology 2021; 93(2): 1099-104.


11.Macedo, Ana et al. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis.Annals of epidemiology 2021; 57: 14-21.



  1. Regalado-Artamendi, Isabel et al. Risk Factors and Mortality of COVID-19 in Patients with Lymphoma: A Multicenter Study. HemaSphere 2021; 5(3):e538.

  2. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with covid-19 outcome in multiple myeloma: First results from the International Myeloma Society Data Set. Blood 2021; 136(26):3033-40.

  3. Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V at al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. The Lancet Oncology 2020; 21(10):1309-16.


15.Palanques-Pastor, Tomás et al. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leukemia & Lymphoma 2021; 62(12):2928-38.



  1. Wu X, Liu L, Jiao J, Yang L, Zhu B, & Li X. Characterisation of clinical, laboratory and imaging factors related to mild vs. severe covid-19 infection: a systematic review and meta-analysis. Annals of medicine 2020; 52:334–44.

  2. Williams PCM, Howard-Jones AR, Hsu P, Palasanthiran P, Gray PE, McMullan BJ, et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology 2020; 52(7):801-8.


18.Government of Republic of Serbia, ‘Vratimo zagrljaj”. 2021. available: https://vakcinacija.gov.rs/vakcine-protiv-covid-19-u-srbiji/



  1. World health organization (WHO)-COVID-19 Vaccine Tracker, available: https://covid19.trackvaccines.org/agency/who/

  2. Centers for Disease Control and Prevention. COVID-19 Vaccines for Moderately to Severely Immunocompromised People. 2021. available: https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/immuno.html (accessed Oct 25, 2021).

  3. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020 Oct; 586(7830):594-9.

  4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-15.

  5. Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021 Dec; 8(12):e934-46.

  6. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5):403-16.

  7. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA 2021; 326(1):35-45.

  8. Italian hematological society (Società italiana di Ematologia). Vaccinazione per COVID-19 nei pazienti con malattie del sangue e sottoposti a trapianto di cellule staminali. 21st March 2021. available:https://siematologia.it/vaccinazione-covid-19-pazienti-malattie-sangue-sottoposti-trapianto-cellule-staminali.

  9. Garassino MC, GiesenN,  Grivas P et al. ESMO Statements for vaccination against COVID-19 in patients with cancer. Published on 22nd December 2020; updated 27th April 2021. available: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination

  10. Committee NCCNC-VA. Preliminary recommendations of the NCCN-COVID-19 Vaccination Advisory Committee. 2020. availabile: https://www.nccn.org/covid-19/pdf/COVID-19_Vaccination_Guidance_V1.0.pdf

  11. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021 Jun; 22(6):765-78.

  12. Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I,et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood 2021; 137(26):3674-6.

  13. Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021 Aug 10; 11(8):142-5.

  14. Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, Weissinger E. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2016; 7:507.

  15. Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M,et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest 2021 Oct; 26:1-9.

  16. Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, et al. How to provide the needed protection from COVID-19 to patients with hematologic malignancies. Blood Cancer Discovery. 2021;2(6):562–7. .

  17. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell 2021 Oct 11; 39(10):1297-9.

  18. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021 May 17; 14(1):81.

  19. Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A,et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell 2021 Aug 9; 39(8):1028-30.


38.Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y,et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021 Jun 10; 137(23):3165-73.



  1. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia 2020 Nov; 34(11):3047-9.

  2. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007 Feb; 122(2):139-45.

  3. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021 Aug; 8(8):e583-92.

  4. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 2021; 11(8):138.

  5. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021 Jul 29; 14(1):119.

  6. Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021 Aug 24; 5(16):3053-61.

Published
2022/03/24
Issue
Vol. 3 No. 1 (2022): Serbian Journal of the Medical Chamber
Section
Reviews